Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

The researchers performed a prospective study to assess plasma leptin concentrations in a group of dialysis patients both before and during short-term rhGH therapy.

Why It Was Studied

Hyperleptinaemia is a well-known biochemical feature found in uraemic patients.

However, little is known about the hormonal regulation of leptin in chronic renal disease.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as crossover.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

Blood samples were taken at 0, 2, 4, and 8 weeks for determination of leptin, GH, and IGF I.

Serum insulin concentrations were assessed at 0 and 4 weeks.

What Was Measured

The subject headings attached to it are Growth Hormone, Kidney Failure, Chronic, Leptin, Osmolar Concentration, Peritoneal Dialysis, Continuous Ambulatory, Recombinant Proteins and Renal Dialysis.

What This Means in Plain Language

The paper is a crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2002 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.